Oncocyte Corp (NASDAQ:IMDX – Get Free Report) dropped 4.4% during trading on Friday . The company traded as low as $4.73 and last traded at $4.74. 74,354 shares traded hands during trading, a decline of 62% from the average session volume of 194,859 shares. The stock had previously closed at $4.96.
Analysts Set New Price Targets
Several equities analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Oncocyte in a research note on Wednesday, June 24th. Wall Street Zen raised shares of Oncocyte from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $12.00.
Check Out Our Latest Analysis on Oncocyte
Oncocyte Price Performance
Oncocyte (NASDAQ:IMDX – Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.28) EPS for the quarter. The business had revenue of $0.03 million during the quarter.
Insider Activity
In related news, major shareholder Broadwood Partners, L.P. bought 250,923 shares of the stock in a transaction that occurred on Monday, April 27th. The stock was purchased at an average cost of $3.64 per share, for a total transaction of $913,359.72. Following the completion of the acquisition, the insider owned 12,684,884 shares in the company, valued at $46,172,977.76. This trade represents a 2.02% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 2.21% of the company’s stock.
About Oncocyte
Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.
Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.
See Also
- Five stocks we like better than Oncocyte
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for Oncocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncocyte and related companies with MarketBeat.com's FREE daily email newsletter.
